CytoReason Secures $80M from OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific to Scale Its AI Disease Models and Establish US Hub in Cambridge, Massachusetts
Revolutionizing IBD Treatment: The CytoReason and CCF Partnership
CytoReason and the Crohn’s & Colitis Foundation Forge Groundbreaking Data Collaboration to Advance IBD Research
Reconstructing disease dynamics for mechanistic insights and clinical benefit
Navigating Drug Development: CytoReason’s Disease Model Platform
Peripheral blood cellular dynamics of rheumatoid arthritis treatment informs about efficacy of response to disease modifying drugs
Making Clinical Trials Better for Everyone in 2023
Roundtable: What do you view as the most disruptive or transformational technology or development on the horizon?
Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances
Technology diffusion strategies for CIOs and the VC mindset
